Loading...
•
Sep 30, 2024
BD Q4 2024 Earnings Report
BD reported strong growth and margin execution, driving performance in Q4 2024.
Key Takeaways
BD reported Q4 revenue of $5.4 billion, a 6.9% increase as reported. GAAP EPS grew 173.6% to $1.45, and adjusted EPS grew 11.4% to $3.81. The company issued FY25 adjusted diluted EPS guidance of $14.25 to $14.60, reflecting growth of about 10% at the midpoint.
Q4 revenue increased 6.9% as reported, 7.4% currency-neutral and 6.2% organic.
Q4 GAAP and adjusted diluted EPS from continuing operations grew 173.6% and 11.4%, respectively.
FY24 cash from continuing operations grew 28.5% to $3.8 billion.
Company issues FY25 revenue guidance including GAAP growth of 8.9% to 9.4%, adjusted currency-neutral growth of 8.8% to 9.3% and organic growth of 4.0% to 4.5%.
BD
BD
BD Revenue by Geographic Location
Revenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
The company provided the following guidance with respect to fiscal 2025. GAAP revenue growth of 8.9% to 9.4% and currency-neutral adjusted revenue growth of 8.8% to 9.3% include the newly acquired APM business. The company's organic revenue growth guidance of 4.0% to 4.5% includes absorbing an impact about 125 basis points from an expected decline in revenues in China and Bioscience and Pharma market dynamics.
Positive Outlook
- GAAP Revenues ~$21.9 to $22.1 billion
- GAAP Revenue Growth 8.9% to 9.4%
- Adjusted Revenue Growth (FXN) 8.8% to 9.3%
- Organic Revenue Growth (FXN) 4.0% to 4.5%
- Adjusted Diluted EPS $14.25 to $14.60
Revenue & Expenses
Visualization of income flow from segment revenue to net income